Blue Jet management on which segments will drive growth for the company
«There is no structural change in the industry and majority of our revenue is coming from the medtech industry, the imaging industry and the dilution of the margins has been a global phenomenon for the chemical industry and we are in performance chemicals,» says VK Singh, COO, Blue Jet Healthcare.
Meanwhile, Shiven Arora, MD, Blue Jet Healthcare says, " See, across three business verticals, we have invoiced to about 400 customers across 39 countries in the past three years. We feel that there is enough and more depth in the customer profile that we have today."
This is a complete OFS and no money is coming in the company. But for the investors, tell us about how do you see yourself growing in the three segments that you have presence in? You have a good presence in the API, CDMO, you have the sweetener segment as well. So going ahead, which one do you believe will drive the growth for the company?
VK Singh: Yes, there is no money coming into the company but then for all three segments, we have demonstrated an excellent growth over the last three, four years and we believe that we will maintain this momentum.
Let me talk about your numbers now, if you look at your margins, they have actually seen a decline and when I talk about decline, I am talking about it being approximately 42% in FY21. Now, if you see in the quarter, in Q1 of FY24, that is, that the margin figure has come down to about 33% or so. If you could tell us why is there a decline in the margins over that period? Also, what is your outlook going ahead for the margin and if possible, if you could give us a sustainable level that you are envisaging when it comes to the margins for your company?
VK Singh: See, there is no structural change in the industry
